ArticleNature communications2026
Structure-informed deep generation enables de novo metabolite annotation in untargeted metabolomics.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolite annotation, especially the discovery of unknown metabolites, remains a fundamental challenge in mass spectrometry-based untargeted metabolomics due to limited reference mass spectra. Here we present MetGenX, a structure-informed encoder-decoder neural network that enables efficient and controllable generation of metabolite structures directly from MS2 spectra. By reformulating the spectrum-to-structure task as a structure-to-structure generation problem, MetGenX significantly improves generation accuracy and chemical space coverage. In independent tests, it achieved top-1 accuracy of 55.9% on 1388 NIST MS2 spectra and 68.5% on 1681 spectra from real biological samples, outperforming existing in silico tools. Its structure-informed design ensures robust performance across both positive and negative ionization modes without retraining. Applying a multi-step annotation workflow to mouse liver untargeted metabolomics data, MetGenX identified two previously uncharacterized metabolites absent from major human metabolome databases. These results demonstrate MetGenX's strong potential to advance de novo metabolite annotation and facilitate the discovery of uncharacterized chemical entities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.